Tirzepatide

DB15171ApprovedInvestigationalProtein Based TherapiesGLP-1 AgonistsGlucose-dependent Insulinotropic Polypeptide Receptor Agonist

Tirzepatide is a dual GIP and GLP-1 receptor agonist used for the treatment of type II diabetes in adults as an adjunct to diet and exercise. Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

Mechanism
Curator reviewed · 11 references
Primary indication
United States Tirzepatide is indicated: - as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. - to...Curator reviewed · 20 structured indications
Formula / weight
C225H348N48O68 · 4810.52 Da
First approval
Canada, 2022 · United States, 2022 · European Union, 2023
Code names
LY3298176
Brand names
  • Mounjaro
  • Zepbound

Resolves to

What you can answer from here — as of November 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
622Drug interactionsStructured to mechanism, not free text
Sign in
237Clinical trialsPhase, status and sponsor resolved per trial
Sign in
20Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
228Marketed productsAcross 7 countries and 6 labellers
Sign in
1ATC codeIncluding every combination product, plus 20 drug categories
Sign in
26+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Tirzepatide, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account